Current Report Filing (8-k)
November 27 2020 - 2:03PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): November 25, 2020
180
LIFE SCIENCES CORP.
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
|
001-38105
|
|
81-3832378
|
(State
or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
830
Menlo Avenue, Suite 100
Menlo
Park, CA
|
|
94025
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: 678-570-6791
None
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on
which
registered
|
Common
Stock, par value $0.0001 per share
|
|
ATNF
|
|
The
NASDAQ Stock Market LLC
|
Warrants
to purchase shares of Common Stock
|
|
ATNFW
|
|
The
NASDAQ Stock Market LLC
|
Item
1.01 Entry into a Material Definitive Agreement.
On November 25, 2020, 180 Life Sciences Corp.
(f/k/a KBL Merger Corp. IV) (the “Company”) and the requisite counterparties to that certain Securities Purchase Agreement,
dated as of June 12, 2020, among the Company, the investors signatory thereto, and Dominion Capital LLC as purchaser agent (the
“Purchase Agreement”), entered into an agreement (the “Amendment Agreement”) to amend the secured convertible
promissory notes in the original aggregate principal amount of $3,601,966.28 (after giving effect to a 10% original issue discount)
that the Company issued pursuant to the Purchase Agreement (the “Notes”) so that the Fixed Conversion Price (as defined
in the Notes)_of the Notes, during the ninety (90) day period following November 6, 2020, shall be equal to the lower of: (A)
ninety-six percent (96%) of the lowest volume weighted average price of the common stock of the Company on the NASDAQ Capital
Market during the five (5) trading day period ending on the trading day immediately prior to the applicable conversion date and
(B) $5.28; provided, that in no event shall the Fixed Conversion Price be lower than $2.00 (in each case, as appropriately adjusted
for any stock dividend, stock split, stock combination, reclassification or similar transaction that proportionately decreases
or increases the number of shares of common stock prior to such date). No other changes were made to the Notes as a result of
the Amendment Agreement.
The
foregoing summary of the Amendment Agreement is qualified in its entirety by reference to the complete text of the Amendment Agreement,
a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits
(d)
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
November 27, 2020
|
180
LIFE SCIENCES CORP.
|
|
|
|
By:
|
/s/
James N. Woody, M.D., Ph.D..
|
|
|
Name:
James N. Woody, M.D., Ph.D.
|
|
|
Title:
Chief Executive Officer
|
2
KBL Merger Corporation IV (NASDAQ:KBLM)
Historical Stock Chart
From Mar 2024 to Apr 2024
KBL Merger Corporation IV (NASDAQ:KBLM)
Historical Stock Chart
From Apr 2023 to Apr 2024